Tech Company Financing Transactions

OncoMed Pharmaceuticals Funding Round

OncoMed Pharmaceuticals, operating out of Redwood City, received $13.9 million from Latterell Venture Partners, Morgenthaler Ventures and The Vertical Group.

Transaction Overview

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

800 Chesapeake Dr.
Redwood City, CA 94063
USA

Phone

(650) 995-8200

Website

www.oncomed.com

Email Address

[email protected]

Overview

OncoMed Pharmaceuticals (NASDAQ: OMED) is discovering and developing monoclonal antibodies and small molecules capable of destroying cancer stem cells, a recently discovered type of cell believed to seed the growth of cancers and underlie cancer's ability to spread and take root in tissues.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

John Lewicki

        

Chief Scientific Officer

Austin Gurney

        

Vice President

Ann Kapoun

        

VP - Finance

Yvonne Li

        

VP - General Counsel

Alicia Hager

        

VP - R & D

Robert Stagg

        

VP - Regulatory Affairs

Jill Henrich

        

Browse more venture capital transactions:

Prev: 9/7/2005: Direct Flow Medical venture capital transaction
Next: 9/8/2005: MetaCarta venture capital transaction

Share this article

News on VC Transactions

We do our best to document all VC transactions involving tech companies. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary